Skip to main content
. 2016 Jan 27;16:30. doi: 10.1186/s12879-016-1345-1

Table 2.

Lumefantrine pharmacokinetic parameters following six-dose artemether-lumefantrine treatment in HIV-1 infected patients who are antiretroviral-naïve or on lopinavir-based antiretroviral therapy

Parameter median (IQR) ARV-naïve group (n = 18) Lopinavir group (n = 16) p value
Cmax (μg/mL) 8.76 (7.80–9.84) 28.15 (14.00–32.95) <0.0001
CV 26.3 % 59.6 %
Tmax (h) 42 (42–66) 67 (51–70) 0.031
CV 35.5 % 27.1 %
AUC(0-inf) (μg.h/mL) 445 (357–553) 2478 (1093–3596) <0.0001
CV 33.5 % 71.0 %
T1/2 (days) 4.1 (2.7–4.4) 4.6 (4.4–5.2) 0.003
CV 25.7 % 15.4 %
Day-7 conc (ng/mL) 336 (230–396) 3170 (1440–5085) <0.0001
CV 54.0 % 98.5 %

Values are shown as medians (interquartile ranges [IQRs]) and Coefficient of variation (CV, %). Cmax, maximal concentration; Tmax, time at the maximal concentration; AUC(0-inf), area under the plasma concentration-time curve, from 0 h to infinity; t1/2, elimination half-life; Day-7 concentration, lumefantrine concentration on day-7;. Statistical significance (p values) calculated using the Kruskal-Wallis test